Reid G. Adler

CIK: 0001924908

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VTGN

Vistagen Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VTGN
Vistagen Therapeutics, Inc.
Jun 30, 2026
Award(A)
Direct
36.8K shares at avg. $0.19$7K
VTGN
Vistagen Therapeutics, Inc.
Apr 7, 2026
Award(A)
Incentive Stock Option (right to buy)
Direct
18.8K shares-
VTGN
Vistagen Therapeutics, Inc.
Apr 7, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
56.2K shares-
VTGN
Vistagen Therapeutics, Inc.
Jun 30, 2025
Award(A)
Direct
7.5K shares at avg. $1.70$13K
VTGN
Vistagen Therapeutics, Inc.
Jun 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A)	36,818	$0.19	$7,073	Direct
Apr 7, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	18,753	-	-	Direct
Apr 7, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	56,247	-	-	Direct
Jun 30, 2025	VTGN Vistagen Therapeutics, Inc.	Award(A)	7,541	$1.70	$12,820	Direct
Jun 23, 2025	VTGN Vistagen Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct

1-5 of 5 transactions

About Adler Reid G.

Adler Reid G. (SEC CIK 0001924908) files insider reports with the SEC as Chief Legal Officer of Vistagen Therapeutics, Inc. (VTGN).

Signal8 holds 4 ownership filings by Adler Reid G., all Form 4s, filed between Jun 25, 2025 and Jul 2, 2026. Those filings report 5 transactions, from Jun 23, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Adler Reid G.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Adler Reid G.

Jun 30, 2026: Grant or award of VTGN shares (Form 4, code A).
Apr 7, 2026: Grants or awards of VTGN derivative securities (2 lines, Form 4, code A).
Jun 30, 2025: Grant or award of VTGN shares (Form 4, code A).
Jun 23, 2025: Grant or award of VTGN derivative securities (Form 4, code A).

Other insiders filing for Vistagen Therapeutics, Inc. (VTGN)

Williamson Douglas J, Officer
Tressler Nick B., Chief Financial Officer
Singh Shawn, President and CEO
Angelov Angel S, Chief Medical Officer
Prince Joshua S., Chief Operating Officer
Cote Elissa S., Chief Corp Development Officer

How to read Form 4 transaction codes